The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Additionally, Braftovi/Mektovi have experienced a 27% global sales increase from the previous year. It is supported by new data showing improved survival rates in colorectal cancer. Lorbrena also ...

As of Q4 2024, Braftovi/Mektovi saw a 27% year-over-year global growth, and recent data showed survival improvements in colorectal cancer. Lorbrena became a standard treatment for lung cancer and ...

Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an ...

Pfizer Inc. announced longer-term follow-up results from the phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of Braftovi (encorafenib) in combination with Mektovi ...

BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...

The combination of Braftovi and Mektovi has been approved for patients with non-small cell lung cancer with the mutation since last year. "All patients with lung cancer should be tested for BRAF ...

The pharmaceutical giant highlighted its ongoing efforts in developing therapies for various cancers, including new data from its BRAFTOVI® + MEKTOVI® study and progress on its investigational ...

The European Commission decision for BRAFTOVI ® (encorafenib) + MEKTOVI ® (binimetinib) is expected later this year. Castres, France, July 25 th, 2024 – Pierre Fabre Laboratories announced today that ...

We look forward to the European Commission's decision to make BRAFTOVI ® + MEKTOVI ® available to non-small cell lung cancer patients in Europe." The CHMP positive opinion is supported by data from ...